We've Rebranded!
HT-ADME is now NE-ADME (New Era of ADME & Beyond) Conference
Thursday, June 16th, 2022
In-Person Event - Novartis Institutes for BioMedical Research, Cambridge, MA
NE-ADME event will be an in-person meeting. However, remote attendance option will also be made available just in case you are still not able to travel.
Plenary Speakers for 2022
![]() |
Brooke M. Rock, PhDDirector, Department of Pharmacokinetics & Drug Metabolism @ Amgen Inc.GalNAc Targeted Liver Delivery of siRNAs and Small Molecules/Bispecific Ab's |
![]() |
Roger D. Kamm, PhDCecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering @ MITVascular and Lymphatic Barrier Function in the Brain and Subcutaneous Compartments |
||
Speakers Confirmed for 2022
![]() |
Mailys De Sousa Mendes, PhDSenior Research Scientist @ Certara UKMechanistic Modeling of Caco-2 Experiments to Estimate Intrinsic Permeability |
![]() |
Li Di, PhDResearch Fellow @ Pfizer, Inc.Prediction Accuracy of Volume of Distribution Using In Vitro, In Vivo, PBPK and QSAR Methods |
||
![]() |
Charles Knutson, PhDAssociate Director @ Novartis Institutes for BioMedical ResearchPanel Discussion |
![]() |
James Kozloski, PhDPrincipal Research Scientist @ IBMPopulations of Models for Virtual Patient/Cohort Construction in ADME/PK |
||
![]() |
Ryan Pelis, PhDSenior Investigator I @ Novartis Institutes for BioMedical ResearchTools Toward Predicting Oral Lymphatic Absorption |
![]() |
Haojing Rong, PhDVice President of Preclinical Development @ Kymera TherapeuticsThe Knowns and Unknowns of ADME/PK of Targeted Protein Degraders |
||
![]() |
Yuanxin Xu, PhDSr. VP of Early Development and Translational Medicine @ Intellia Therapeutics, Inc.Of Mice and Man: Path to Clinical CRISPR/Cas9 Genome Editing Therapeutic Development |
Doug Burdette, PhDDirector of DMPK and Clinical Pharmacology @ Moderna Therapeutics, Inc.Title TBA |
|||
![]() |
Dipen Vyas, PhDStudy Director (ADME-Tox) @ BioIVTLong-term HEPATOPAC® Cultures: Model Validation for ADME-Tox Applications |
Panel Discussion: Expedited Drug Discovery Post-COVID |
Participants: Brooke Rock, Amgen Doug Burdette & Lei Ci, Moderna Charlie Knutson, Novartis |
SESSION I: Advances in ADME of New Modalities
SESSION II: Novel In Silico Tools for ADME in Drug Discovery
SESSION III: Contributions of Vascular and Lymphatic Compartments to Drug Absorption
SESSION IV: ADME of COVID Therapeutics and Beyond